There is an increasing interest in developing molecule-specific antibodies, since neutralization of tau aggregates seems to be a crucial step in progressive supranuclear palsy treatment, and novel trials are suspected to bring positive results. This evidence concerns the gene MAPT and Classical progressive supranuclear palsy.